Member Info for ThinIce

Need to change my broker!!!

Lloyds Stockbrokers are quoting 18.4 to buy, so these are almost certainly sells. The price is up and the ask is 19p. This to me suggests that the MMs are discouraging buying as they are filling an order. I expect we may see a large buy later today. Anyone esle think this could be the case?

Anyone else think there may be an order being filled?

It's hard to predict anything when we are left in the dark! There must be something they can tell their shareholders about how our money is being spent. It's all a bit disappointing after December's news! Fastnet were slow in their updates but at least they held a few investor presentations and on line interviews ... by comparison, this lot are positively 'sloth like'.

Hi euitrder Would you mind expanding on the last part of your mail of 20.19 please? Can you tell us what the interesting occurance was and how this may impact on AMYT (i.e. NASDAQ listing). I dont have time to dig around trying to find the answer. Radar - I think when we get news of the P3, the share price will start to move up. If that is the case and we see significant gains, my plan is to be out before the results.

We were advised that the Episalvan P3 was due to start in this quarter. If that's still the timetable then I would expect to hear news of its commencement! There again, if for any reason the timetable has changed then I would expect that we would be advised of that too within this quarter. Other than that, as Radar says 'not got a clue'.

Hi EB Other than what has been said in previous announcements about P3 commencing in Q1 2017, do you have any other information? Your use of the word imminently makes me think there has been a further announcement! Thanks TI

And another even bigger delayed buy. I can only think that there is a big sell order in the background. If the market makers job is to create a market, you would have thought the level of activity over the last few days would have created the stimulus to move the price!

Someone seems to be building a stake!

Novelion (argerion's parent) have a number of products we could no doubt be selling also (subject to approval in our territories).

There will be other licensing deals with this company to come in my view.

Potentially $3M in sales straight away!

Thanks ShrewDEds. I couldn't work out how to copy it on my phone.

Not sure it's been mentioned on here, but Stifel (joint broker) have given it a 49p price target in their latest note. The note is available via the ************* web-site (Tom Winnifrith), but you have to register! I hope they are right! Either way, I think the upward traction will continue over the next week as more investors catch on!

Lets hope they're filling an order!

I hate to say it Kev, but I think it will keep dropping until we get news and I don't think anyone is expecting that until the New Year. It would be a brave investor that piled in now! I still don't really understand what it is that all these highly paid executives are doing. The Episalvan and AP102 work should now be outsourced and they state in the half year report that they don't see sales of Imlan increasing in 2017. Anyone care to speculate.....?

Hi equitrader Harry Stratford is the Non-Executive Chairman. The Times ran an article on the role of NEDs generally and whether they should hold shares and/or options in the companies in which they have a supervisory role. It could be said that by holding shares (at the least) they are aligning themselves with the interests of shareholders. The flip side is that they have an advantage over regular shareholders and may even seek to influence the direction of the company for selfish purposes. The conclusion to the article was as follows: "Perhaps, the short answer to the question we started with is this: NEDs should hold some shares to align themselves with the interests of other shareholders, but should not be holding so many shares, nor should their remuneration be tied to performance, such that their independence or objective judgment is affected." Indeed, the article infers that many Non-Executives believe it is improper, particularly where they have access to information that other shareholders do not have. Furthermore, it is always harder to a Non-Executive to sell shares as it can be seen a vote of no confidence in the management, when in fact there may be a very genuine reason for selling. It follows therefore that the Non-Executive does not have the same freedom to trade as other shareholders may have. I only mention this as it was an issue that you have raised a number of times in relation to Harry Startford. I don't have an opinion either way but whilst there is next to nothing happening here, we might as well talk about something!! Best wishes TI

The costs will be those associated in the main with the EB phase 3 study that starts in January 2017 (I believe). In light of this time frame, I suspect that some of these costs will have been incurred already (possibly inc. an up front fee) On that basis, I would think the figure probably can be taken as representative of cash burn at this point in time.

Thanks mytrader It's mentioned under 'interims' (first page second bullet) of the research note.

Alfacomp - I believe it's in the half yearly report. I'll try and dig it out unless anyone else has it immediately to hand!